Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2017
Price :
$35
*
At a glance
- Drugs Imaprelimab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Prothena
- 09 Jun 2016 Results published in Prothena Corporation media release.
- 09 Jun 2016 Results from this study presented at The European League Against Rheumatism (EULAR) 17th Annual European Congress of Rheumatology, as per Prothena Corporation media release.
- 14 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.